Year in Review: Multiple Sclerosis

Year in Review: Multiple Sclerosis

Publication date: Dec 02, 2019

Two other MS drugs earned OKs this year, the first being siponimod (Mayzent) for adult patients with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

The drug was the first oral agent for secondary progressive MS (SPMS) with active disease and the first treatment specifically approved for patients with active SPMS in over 15 years.

The anti-CD20 monoclonal antibody ofatumumab (Arzerra) — approved for chronic lymphocytic leukemia but investigational for MS — outperformed teriflunomide (Aubagio) in reducing annualized relapse rate (ARR), according to two phase III studies presented at the 2019 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress in September.

The trial aimed to place ponesimod within the spectrum of the oral MS drugs, “which are getting to be, more and more, the standard treatment,” OPTIMUM researcher Ludwig Kappos, MD, of University Hospital of Basel in Switzerland, told MedPage Today.

Also at ACTRIMS, an extension study of patients from the CARE-MS II trial showed that over eight years, alemtuzumab (Lemtrada) continued to show benefits in clinical outcomes, lesion load, and brain volume loss in relapsing-remitting MS. Interim data from the real-world ESTEEM study presented at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting in June showed that dimethyl fumarate was effective and safe for black patients with relapsing-remitting MS. And in the phase IIIb ASSESS trial, also presented at CMSC, fingolimod (Gilenya) bested glatiramer acetate (Copaxone) at lowering relapses and disease activity in relapsing-remitting MS patients.

A trial published in January showed that, in patients with highly active relapsing-remitting MS, stem cell transplantation was more effective than disease-modifying therapies (DMTs), though ocrelizumab and alemtuzumab were not included in the study.

At ACTRIMS, a small study looked at patients with stable relapsing-remitting MS who stopped DMTs and found they had similar times to relapses, inflammatory events, and disability progression as stable patients who remained on treatment.

At ECTRIMS, researchers showed that levels of serum neurofilament light (NfL) increased six years before the clinical onset of MS. Research presented at ACTRIMS indicated that early levels of serum NfL may pinpoint which MS patients are at risk for more severe disease.

Concepts Keywords
Alemtuzumab Chemotherapy
ASCLEPIOS MRI
Aurora Teriflunomide
Barcelona Transplantation
Basel Cladribine
Biomarker Ofatumumab
Brain Ocrelizumab
California Sanofi
CARE Breakthrough therapy
CD20 Drugs
Chemotherapy Monoclonal antibodies
Chronic Lymphocytic Leukemia Multiple sclerosis
Cladribine Medicine
Clinical Trial Immunosuppressants
Cohort Medical specialties
Colorado Chemotherapy
Copaxone Vaccinations
Disability Immunization
FDA Syndrome
Fingolimod MS
Fumarate Chronic lymphocytic leukemia
Gadolinium Risk severe disease
Gastrointestinal Yearly flu
Gilenya
Glatiramer Acetate
Hebron
Immunization
Immunosuppressive Drugs
Inflammatory Events
Insurance
Interferon Beta
Lesion
Medicare
Monoclonal Antibody
MRI
MS 1
Multiple Sclerosis
Natalizumab
Neurofilament
Neurology
NfL
Obesity
Phase III
PhD
Phosphate
Physical Disability
Placebo
Progressive
Puberty
Rebif
Receptor
Relapse
Rituxan
Rituximab
San Francisco
Serum
Spain
Spectrum
Sphingosine
Spinal Cord
Switzerland
Tanuja
Tysabri
Vaccination
Wales

Semantics

Type Source Name
drug DRUGBANK Teriflunomide
drug DRUGBANK Ofatumumab
drug DRUGBANK Cladribine
disease MESH relapses
drug DRUGBANK Siponimod
disease MESH syndrome
disease MESH Obesity
drug DRUGBANK Gadolinium
disease MESH development
drug DRUGBANK Ocrelizumab
drug DRUGBANK Rituximab
drug DRUGBANK Ponesimod
drug DRUGBANK Sphingosine
drug DRUGBANK Phosphate ion
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Alemtuzumab
drug DRUGBANK Fingolimod
drug DRUGBANK Glatiramer
drug DRUGBANK Acetate ion
drug DRUGBANK Natalizumab
drug DRUGBANK Tropicamide
drug DRUGBANK Monomethyl fumarate
drug DRUGBANK Dimethyl fumarate
disease MESH Multiple Sclerosis

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *